Hubungan Diabetes Mellitus Tipe 2 dengan Kejadian Benign Prostatic Hyperplasia di Rumah Sakit Umum Pusat Haji Adam Malik Medan Tahun 2015
DAFTAR PUSTAKA
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
The National Institute of Diabetes and Digestive and Kidney Disease.
Prostate Enlargement: Benign Prostatic Hyperplasia [Internet]. 2014.
Available
from:
https://www.niddk.nih.gov/health-information/healthtopics/urologic-disease/benign-prostatic-hyperplasia-bph/Pages/facts.aspx
American Urological Association. American Urological Association
Guideline: Management of Benign Prostatic Hyperplasia (BPH) [Internet].
American Urological Association Education and Research, Inc.; 2010.
Available from: https://www.auanet.org/common/pdf/education/clinicalguidance/Benign-Prostatic-Hyperplasia.pdf
Spatafora S, Casarico A, Fandella A, Galetti C, Hurle R, Mazzini E, et al.
Evidence-based guidelines for the treatment of lower urinary tract symptoms
related to uncomplicated benign prostatic hyperplasia in Italy: updated
summary from AURO.it.- PubMed – NCBI. Ncbi.nlm.nih.gov. 2012.
Kapoor A. Benign prostatic hyperplasia (BPH) management in the primary
care setting. Can J Urol. 2012;19(Suppl 1):10-7.
Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol.
2005;7(Suppl 9):S3.
Edwards J. Diagnosis and Management of Benign Prostatic Hyperplasia –
American Family Physician. Aafp.org. 2008.
Deters LA. Benign Prostatic Hypertrophy: Practice Essentials, Background,
Anatomy [Internet]. Emedicine.medscape.com. 2015 [cited 30 April 2016].
Available
from:
http://www.emedicine.medscape.com/article/437359overview
Ikatan Ahli Urologi Indonesia. Clinical Pathway 10 Penyakit Urologi
Tersering [Internet]. Ikatan Ahli Urologi Indonesia;2015. Available from:
http://www.iaui.or.id/ast/file/CLINICAL_PATHWAY_(CP%20IAUI).pdf
Mochtar C, Umbas R, Soebadi D, Rasyid N, Nugroho B, Purnomo B et al.
Panduan Penatalaksanaan Klinis Pembesaran Prostat Jinak (Benign Prostatic
Hyperplasia/BPH) [Internet]. Jakarta: Ikatan Ahli Urologi Indonesia; 2015.
Available from: http://www.iaui.or.id/ast/file/Guideline_BPH_(2015).pdf
Patel ND, Parsons JK. Epidemiology and etiology of benign prostatic
hyperplasia and bladder outlet obstruction. Indian J Urol. 2014;30(2):170.
Chen Z, Miao L, Gao X, Wang G, Xu Y. Effect of obesity and
hyperglycemia on benign prostatic hyperplasia in elderly patients with
newly diagnosed type 2 diabetes. Int J Clin Exp Med. 2015;8(7):1128911294.
Tseng C. Benign prostatic hyperplasia is a significant risk factor for bladder
cancer in diabetic patients: a population-based cohort study using the
National Health Insurance in Taiwan. BMC Cancer. 2013;13(1):1.
Breyer BN, Sarma AV. Hyperglycemia and Insulin Resistance and the Risk
of BPH/LUTS: an Update of Recent Literature. Curr Urol Rep. 2014;15(12).
32
Universitas Sumatera Utara
33
14.
Ross AE, Rodriguez R. Development, Molecular Biology, and Physiology
of the Prostate. In: Wein A, Kavoussi L, Partin A, Peters C, ed. by.
Campbell-Walsh Urology. 11th ed. Philadelphia: Elsevier, Inc.; 2016. p.
2393-2396.
15. Muruve NA. Prostate Anatomy: Overview, Gross Anatomy, Microscopic
Anatomy [Internet]. Emedicine.medscape.com. 2013 [cited 3 May 2016].
Available from: http://www.emedicine.medscape.com/article/1923122overview
16. Paulsen F, Weschke J. Sistem Urinarium Eferen. In: Pendit BU, Sugiharto
L. by. Sobotta : Atlas Anatomi Manusia Jilid 2. 23rd ed. Jakarta: EGC, Inc.;
2012. p. 177.
17. Bushman W. Male Genital System and Lower Urinary Tract. In: Kumar V,
Abbas A, Aster J, ed. by. Robbins' Basic Pathology. 9th ed. Philadelphia:
Elsevier, Inc.; 2013. p. 663.
18. Presti J, Kane C, Shinohara K, Carroll P. Neoplasms of the Prostate Gland.
In: Tanagho EMcAninch J, ed. by. Smith's General Urology. 17th ed. New
York: The McGraw-Hill Companies, Inc.; 2008. p. 348-350.
19. Giri A, Edwards TL, Motley SS, Byerly SH, Fowke JH. Genetic
Determinants of Metabolism and Benign Prostate Enlargement: Associations
with Prostate Volume. PLOS ONE. 2015;10(7):e0132028.
20. Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impot Res.
2008;20:S11-S18.
21. Vuichoud C, Loughlin KR. Benign prostatic hyperplasia: epidemiology,
economics and evaluation. Can J Urol. 2015;22(5 Suppl 1):1-6.
22. Trumble BC, Stieglitz J, Rodriguez DE, Linares EC, Kaplan HS, Gurven
MD. Challenging the Inevitability of Prostate Enlargement: Low Levels of
Benign Prostatic Hyperplasia Among Tsimane Forage-Horticulturalist. J
Gerontol A Biol Sci Med Sci. 2015;70(10):1262-8.
23. Lepor H. Pathophysiology, Epidemiology, and Natural History of Benign
Prostatic Hyperplasia. Rev Urol. 2004;6(Suppl 9):S3.
24. Nandeesha H. Benign prostatic hyperplasia: Dietary and metabolic risk
factors. Int Urol Nephro. 2008;40(3):649-56.
25. Parsons J. Benign Prostatic Hyperplasia and Male Lower Urinary Tract
Symptoms: Epidemiology and Risk Factors. Curr Bladder Dysfunct Rep.
2010;5(4):212-218.
26. Yelsel K, Alma E, Eken A, Gulum M, Ercil H, Ayyildiz A. Effect of obesity
on International Prostate Symptom Score and prostate volume. Urol Ann.
2015.
27. Ylitalo AW, Santucci RA, Roberts KE. Digital Rectal Examination
[Internet]. Emedicine.medscape.com. 2015 [cited 16 May 2016]. Available
from: http://www.emedicine.medscape.com/article/1948001-overview
28. Gale EAM, Anderson JV. Diabetes mellitus and other disorders of
metabolism. In: Kumar P, Clark M. Clinical Medicine. 7th ed. Philadelphia:
Elsevier, Inc.; 2009. p. 1029.
29. American Diabetes Association. Diagnosis and classification of diabetes
mellitus. Diabetes care. 2010;33(Suppl 1):S62-S69.
Universitas Sumatera Utara
34
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
Inzucchi S, Bergenstel R, Buse J, Diamant M, Ferrannini E, et al.
Management in Type 2 Diabetes: A Patient-Centerd Approach: Position
Statement of the American Diabetes Association for the Study of Diabetes
(EASD). Diabetes Care. 2012;35(6):1364-1379
Patel P, Macerollo A. Diabetes Mellitus: Diagnosis and Screening –
American Family Physician. Aafp.org. 2010.
Farsani SF, Van Der Aa MP, Van Der Vorst MM, Knibbe CA, De Boer A.
Global trends in the incidence and prevalence of type 2 diabetes in children
and adolescents: a systematic review and evaluation of methodological
approach- PubMed - NCBI. Ncbi.nlm.nih.gov. 2013.
Khardori R. Type 2 Diabetes Mellitus: Practice Essentials, Background,
Pathophysiology [Internet]. Emedicine.medscape.com. 2015 [cited 25 May
2016]. Available from: http://emedicine.medscape.com/article/117853overview
Kaku K. Pathophysiology of Type 2 Diabetes and Its Treatment Policy.
JMAJ. 2010;53(1):41-46.
Olafsdottir E, Aspelund T, Sirgudsson G, Thorsson B, Benediktsson R,
Harris T et al. Unfavourable risk factors for type 2 diabetes mellitus are
already apparent more than a decade before onset in population-based study
of older persons: from the Age, Gene/Environment Susceptibility–Reykjavik
Study (AGES-Reykjavik). Eur J Epidemiol. 2009;24(6):307-314
Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI.
Penyajian Pokok-Pokok Hasil Riset Kesehatan Dasar 2013. Jakarta: Badan
Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI; 2013.
PERKENI. Konsensus Pengendalian dan Pencegahan Diabetes Melitus Tipe
2 di Indonesia. Jakarta: Perkumpulan Endokrinologi Indonesia; 2011.
Sarma A, Burke J, Jacobson D, McGree M, St. Sauver J, Girman C et al.
Associations Between Diabetes and Clinical Markers of Benign Prostatic
Hyperplasia Among Community-Dwelling Black and White Men. Diabetes
Care. 2007;31(3):476-482.
Corona G, Vignozzi L, Rastrelli G, Lotti F, Cipriani S, Maggi M. Benign
Prostatic Hyperplasia: A New Metabolic Disease of the Aging Male and Its
Correlation with Sexual Dysfunctions. Int J Endocrinol. 2014:1-14.
Ghazali M, Sastromihardjo S, Soedjarwo S, Soelaryo T, Pramulyo H. Saudi
cross-sectional. In: Sastroasmoro S, Ismael S, ed. by. Dasar-dasar
Metodologi Penelitian Klinis. 4th ed. Jakarta: Sagung Seto; 2013. p. 130144.
Dahlan M. Besar Sampel Aksis Deskriptif. In: Dahlan M, ed. by. Besar
Sampel dalan Penelitian Kedokteran dan Kesehatan. 4th ed. Jakarta:
Epidemiologi Indonesia; 2016. p. 11-68.
Yuri P, Wangge G, Abshari F, Satjakoesoemah Al, Perdana NR, Wijaya CD,
et al. Indonesian prostate cancer risk calculator (IPCRC): an application for
predicting prostate cancer risk (a multicenter study).- Pubmed – NCBI.
Ncbi.mlm.nih.gov. 2015.
Universitas Sumatera Utara
35
43.
44.
45.
46.
47.
48.
Amalia R. Faktor-Faktor Risiko terjadinya Pembesaran Prostat Jinak (Studi
Kasus di RS Dr. Kariadi, RSI Sultan Agung, RS Roemani Semarang). Jurnal
Epidemiologi. 2008.
Temml C, Obermayr R, Marszalek M, Rauchenwald M, Madersbacher S,
Ponholzer A. Are lower urinary tract symptoms influenced by metabolic
syndrome?. Urol. 2009;73(3):544-8.
Burke JP, Jacobson DJ, McGree ME, Roberts RO, Girman CJ, Lieber MM,
Jacobsen SJ. Diabetes and benign prostatic hyperplasia progression in
Olmsted County, Minnesota. Urol. 2006;67(1):22-5.
Yin Z, Yang JR, Rao JM, Song W, Zhou KQ. Association between benign
prostatic hyperplasia, body mass index, and metabolic syndrome in Chinese
men. Asian J Andro. 2015;17(5):826.
Van Den Eeden SK, Ferrara A, Shan J, Jacobsen SJ, Quinn VP, Haque R,
Quesenberry CP. Impact of type 2 diabetes on lower urinary tract symptoms
in men: a cohort study. BMC Urol. 2013;13(1):1.
Gao Y, Wang M, Zhang H, Tan A, Yang X, Qin X, Hu Y, Zhang Y, Liao
M, Mo Z. Are metabolic syndrome and its components associated with
lower urinary tract symptoms? Results from a Chinese male population
survey. Urol. 2012;79(1):194-201.
Universitas Sumatera Utara
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
The National Institute of Diabetes and Digestive and Kidney Disease.
Prostate Enlargement: Benign Prostatic Hyperplasia [Internet]. 2014.
Available
from:
https://www.niddk.nih.gov/health-information/healthtopics/urologic-disease/benign-prostatic-hyperplasia-bph/Pages/facts.aspx
American Urological Association. American Urological Association
Guideline: Management of Benign Prostatic Hyperplasia (BPH) [Internet].
American Urological Association Education and Research, Inc.; 2010.
Available from: https://www.auanet.org/common/pdf/education/clinicalguidance/Benign-Prostatic-Hyperplasia.pdf
Spatafora S, Casarico A, Fandella A, Galetti C, Hurle R, Mazzini E, et al.
Evidence-based guidelines for the treatment of lower urinary tract symptoms
related to uncomplicated benign prostatic hyperplasia in Italy: updated
summary from AURO.it.- PubMed – NCBI. Ncbi.nlm.nih.gov. 2012.
Kapoor A. Benign prostatic hyperplasia (BPH) management in the primary
care setting. Can J Urol. 2012;19(Suppl 1):10-7.
Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol.
2005;7(Suppl 9):S3.
Edwards J. Diagnosis and Management of Benign Prostatic Hyperplasia –
American Family Physician. Aafp.org. 2008.
Deters LA. Benign Prostatic Hypertrophy: Practice Essentials, Background,
Anatomy [Internet]. Emedicine.medscape.com. 2015 [cited 30 April 2016].
Available
from:
http://www.emedicine.medscape.com/article/437359overview
Ikatan Ahli Urologi Indonesia. Clinical Pathway 10 Penyakit Urologi
Tersering [Internet]. Ikatan Ahli Urologi Indonesia;2015. Available from:
http://www.iaui.or.id/ast/file/CLINICAL_PATHWAY_(CP%20IAUI).pdf
Mochtar C, Umbas R, Soebadi D, Rasyid N, Nugroho B, Purnomo B et al.
Panduan Penatalaksanaan Klinis Pembesaran Prostat Jinak (Benign Prostatic
Hyperplasia/BPH) [Internet]. Jakarta: Ikatan Ahli Urologi Indonesia; 2015.
Available from: http://www.iaui.or.id/ast/file/Guideline_BPH_(2015).pdf
Patel ND, Parsons JK. Epidemiology and etiology of benign prostatic
hyperplasia and bladder outlet obstruction. Indian J Urol. 2014;30(2):170.
Chen Z, Miao L, Gao X, Wang G, Xu Y. Effect of obesity and
hyperglycemia on benign prostatic hyperplasia in elderly patients with
newly diagnosed type 2 diabetes. Int J Clin Exp Med. 2015;8(7):1128911294.
Tseng C. Benign prostatic hyperplasia is a significant risk factor for bladder
cancer in diabetic patients: a population-based cohort study using the
National Health Insurance in Taiwan. BMC Cancer. 2013;13(1):1.
Breyer BN, Sarma AV. Hyperglycemia and Insulin Resistance and the Risk
of BPH/LUTS: an Update of Recent Literature. Curr Urol Rep. 2014;15(12).
32
Universitas Sumatera Utara
33
14.
Ross AE, Rodriguez R. Development, Molecular Biology, and Physiology
of the Prostate. In: Wein A, Kavoussi L, Partin A, Peters C, ed. by.
Campbell-Walsh Urology. 11th ed. Philadelphia: Elsevier, Inc.; 2016. p.
2393-2396.
15. Muruve NA. Prostate Anatomy: Overview, Gross Anatomy, Microscopic
Anatomy [Internet]. Emedicine.medscape.com. 2013 [cited 3 May 2016].
Available from: http://www.emedicine.medscape.com/article/1923122overview
16. Paulsen F, Weschke J. Sistem Urinarium Eferen. In: Pendit BU, Sugiharto
L. by. Sobotta : Atlas Anatomi Manusia Jilid 2. 23rd ed. Jakarta: EGC, Inc.;
2012. p. 177.
17. Bushman W. Male Genital System and Lower Urinary Tract. In: Kumar V,
Abbas A, Aster J, ed. by. Robbins' Basic Pathology. 9th ed. Philadelphia:
Elsevier, Inc.; 2013. p. 663.
18. Presti J, Kane C, Shinohara K, Carroll P. Neoplasms of the Prostate Gland.
In: Tanagho EMcAninch J, ed. by. Smith's General Urology. 17th ed. New
York: The McGraw-Hill Companies, Inc.; 2008. p. 348-350.
19. Giri A, Edwards TL, Motley SS, Byerly SH, Fowke JH. Genetic
Determinants of Metabolism and Benign Prostate Enlargement: Associations
with Prostate Volume. PLOS ONE. 2015;10(7):e0132028.
20. Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impot Res.
2008;20:S11-S18.
21. Vuichoud C, Loughlin KR. Benign prostatic hyperplasia: epidemiology,
economics and evaluation. Can J Urol. 2015;22(5 Suppl 1):1-6.
22. Trumble BC, Stieglitz J, Rodriguez DE, Linares EC, Kaplan HS, Gurven
MD. Challenging the Inevitability of Prostate Enlargement: Low Levels of
Benign Prostatic Hyperplasia Among Tsimane Forage-Horticulturalist. J
Gerontol A Biol Sci Med Sci. 2015;70(10):1262-8.
23. Lepor H. Pathophysiology, Epidemiology, and Natural History of Benign
Prostatic Hyperplasia. Rev Urol. 2004;6(Suppl 9):S3.
24. Nandeesha H. Benign prostatic hyperplasia: Dietary and metabolic risk
factors. Int Urol Nephro. 2008;40(3):649-56.
25. Parsons J. Benign Prostatic Hyperplasia and Male Lower Urinary Tract
Symptoms: Epidemiology and Risk Factors. Curr Bladder Dysfunct Rep.
2010;5(4):212-218.
26. Yelsel K, Alma E, Eken A, Gulum M, Ercil H, Ayyildiz A. Effect of obesity
on International Prostate Symptom Score and prostate volume. Urol Ann.
2015.
27. Ylitalo AW, Santucci RA, Roberts KE. Digital Rectal Examination
[Internet]. Emedicine.medscape.com. 2015 [cited 16 May 2016]. Available
from: http://www.emedicine.medscape.com/article/1948001-overview
28. Gale EAM, Anderson JV. Diabetes mellitus and other disorders of
metabolism. In: Kumar P, Clark M. Clinical Medicine. 7th ed. Philadelphia:
Elsevier, Inc.; 2009. p. 1029.
29. American Diabetes Association. Diagnosis and classification of diabetes
mellitus. Diabetes care. 2010;33(Suppl 1):S62-S69.
Universitas Sumatera Utara
34
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
Inzucchi S, Bergenstel R, Buse J, Diamant M, Ferrannini E, et al.
Management in Type 2 Diabetes: A Patient-Centerd Approach: Position
Statement of the American Diabetes Association for the Study of Diabetes
(EASD). Diabetes Care. 2012;35(6):1364-1379
Patel P, Macerollo A. Diabetes Mellitus: Diagnosis and Screening –
American Family Physician. Aafp.org. 2010.
Farsani SF, Van Der Aa MP, Van Der Vorst MM, Knibbe CA, De Boer A.
Global trends in the incidence and prevalence of type 2 diabetes in children
and adolescents: a systematic review and evaluation of methodological
approach- PubMed - NCBI. Ncbi.nlm.nih.gov. 2013.
Khardori R. Type 2 Diabetes Mellitus: Practice Essentials, Background,
Pathophysiology [Internet]. Emedicine.medscape.com. 2015 [cited 25 May
2016]. Available from: http://emedicine.medscape.com/article/117853overview
Kaku K. Pathophysiology of Type 2 Diabetes and Its Treatment Policy.
JMAJ. 2010;53(1):41-46.
Olafsdottir E, Aspelund T, Sirgudsson G, Thorsson B, Benediktsson R,
Harris T et al. Unfavourable risk factors for type 2 diabetes mellitus are
already apparent more than a decade before onset in population-based study
of older persons: from the Age, Gene/Environment Susceptibility–Reykjavik
Study (AGES-Reykjavik). Eur J Epidemiol. 2009;24(6):307-314
Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI.
Penyajian Pokok-Pokok Hasil Riset Kesehatan Dasar 2013. Jakarta: Badan
Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI; 2013.
PERKENI. Konsensus Pengendalian dan Pencegahan Diabetes Melitus Tipe
2 di Indonesia. Jakarta: Perkumpulan Endokrinologi Indonesia; 2011.
Sarma A, Burke J, Jacobson D, McGree M, St. Sauver J, Girman C et al.
Associations Between Diabetes and Clinical Markers of Benign Prostatic
Hyperplasia Among Community-Dwelling Black and White Men. Diabetes
Care. 2007;31(3):476-482.
Corona G, Vignozzi L, Rastrelli G, Lotti F, Cipriani S, Maggi M. Benign
Prostatic Hyperplasia: A New Metabolic Disease of the Aging Male and Its
Correlation with Sexual Dysfunctions. Int J Endocrinol. 2014:1-14.
Ghazali M, Sastromihardjo S, Soedjarwo S, Soelaryo T, Pramulyo H. Saudi
cross-sectional. In: Sastroasmoro S, Ismael S, ed. by. Dasar-dasar
Metodologi Penelitian Klinis. 4th ed. Jakarta: Sagung Seto; 2013. p. 130144.
Dahlan M. Besar Sampel Aksis Deskriptif. In: Dahlan M, ed. by. Besar
Sampel dalan Penelitian Kedokteran dan Kesehatan. 4th ed. Jakarta:
Epidemiologi Indonesia; 2016. p. 11-68.
Yuri P, Wangge G, Abshari F, Satjakoesoemah Al, Perdana NR, Wijaya CD,
et al. Indonesian prostate cancer risk calculator (IPCRC): an application for
predicting prostate cancer risk (a multicenter study).- Pubmed – NCBI.
Ncbi.mlm.nih.gov. 2015.
Universitas Sumatera Utara
35
43.
44.
45.
46.
47.
48.
Amalia R. Faktor-Faktor Risiko terjadinya Pembesaran Prostat Jinak (Studi
Kasus di RS Dr. Kariadi, RSI Sultan Agung, RS Roemani Semarang). Jurnal
Epidemiologi. 2008.
Temml C, Obermayr R, Marszalek M, Rauchenwald M, Madersbacher S,
Ponholzer A. Are lower urinary tract symptoms influenced by metabolic
syndrome?. Urol. 2009;73(3):544-8.
Burke JP, Jacobson DJ, McGree ME, Roberts RO, Girman CJ, Lieber MM,
Jacobsen SJ. Diabetes and benign prostatic hyperplasia progression in
Olmsted County, Minnesota. Urol. 2006;67(1):22-5.
Yin Z, Yang JR, Rao JM, Song W, Zhou KQ. Association between benign
prostatic hyperplasia, body mass index, and metabolic syndrome in Chinese
men. Asian J Andro. 2015;17(5):826.
Van Den Eeden SK, Ferrara A, Shan J, Jacobsen SJ, Quinn VP, Haque R,
Quesenberry CP. Impact of type 2 diabetes on lower urinary tract symptoms
in men: a cohort study. BMC Urol. 2013;13(1):1.
Gao Y, Wang M, Zhang H, Tan A, Yang X, Qin X, Hu Y, Zhang Y, Liao
M, Mo Z. Are metabolic syndrome and its components associated with
lower urinary tract symptoms? Results from a Chinese male population
survey. Urol. 2012;79(1):194-201.
Universitas Sumatera Utara